PLUVICTO is targeted therapy
PLUVICTO is a targeted therapy that delivers radiation treatment directly to PSMA+ cells.
1. PSMA is a biomarker that is expressed on prostate cancer cells and can be seen on a PSMA PET scan. PLUVICTO can be used to target PSMA-positive cancer cells.
2. Once PLUVICTO attaches to PSMA, it is absorbed by the cell.
3. Once PLUVICTO is absorbed by the cell, it releases radiation that can damage and kill cells that are PSMA+ and other nearby cells.
PSMA+, prostate-specific membrane antigen positive.